Natriumklorid Fresenius Kabi 9 mg/ml infusjonsvæske
Sponsors
Sorlandet Sykehus HF, Rigshospitalet, Oslo University Hospital HF, St. Olavs Hospital HF, Norges Idrettshoegskole
Conditions
Autism spectrum disorderBenzodiazepine dependence (F13.2)Coma and other disorders of consciousness due to acute traumatic and non-traumatic brain injuryIdiopathic painful small fiber neuropathy or sensory neuronopathy.The participants do not have any medical condition
Phase 1
Boosting recovery through excitation of arousal and awareness in comatose patients: The BREA2KTHROUGH trial
WithdrawnCTIS2023-503617-30-01
Target: 384Updated: 2023-11-20
Boosting recovery through excitation of arousal and awareness in comatose patients: Dose finding study (BREA2KTHROUGH DOSEFINDER)
RecruitingCTIS2023-503617-30-02
Start: 2025-02-26Target: 384Updated: 2025-02-27
Phase 2
Effect of intravenous immunoglobulins on painful sensory neuropathy evaluated by aggregated N-of-one trials
Not yet recruitingCTIS2022-501717-31-00
Target: 30Updated: 2024-12-19
A randomized, placebo-controlled, double-blind, 3-period cross-over study in youth with autism spectrum disorders evaluating neural plasticity and learning after a single administration of intranasal oxytocin
Not yet recruitingCTIS2023-506826-36-00
Target: 98Updated: 2025-12-03
A randomized, placebo-controlled, double-blind, 2-period cross-over study in youth with autism spectrum disorders evaluating social and repetitive behaviors after four weeks of twice daily-doses of 24IU of intranasally administered oxytocin
Not yet recruitingCTIS2024-512387-56-00
Target: 128Updated: 2024-10-09
Effects of intranasal oxytocin in the treatment of benzodiazepine withdrawal: A pilot randomized parallel group placebo-controlled trial
Not yet recruitingCTIS2024-516262-11-00
Target: 60Updated: 2025-02-27
Endocrinological Support Therapy After Military Operations
Not yet recruitingCTIS2026-525935-18-01
Target: 22Updated: 2026-10-08